export const  topics = ["Myeloma", "Test Input", "Cart", "Macbook Repair", "Visa", "Housing", "Social Security"];
export const contents = [
    `After initial diagnostic workup, What are the clinical findings?
    --If Multiple Myeloma (symptomatic), Perform primary treatment through myeloma therapy. Is the patient a transplant candidate?
    ----If Yes, Is the patient frail?
    ------If No (frail score <2), Does the patient have either renal insufficiency or peripheral neuropathy?
    --------If No, Is the patient standard or high risk?
    ----------If Standard risk, The treatments for the patient are Bortezomib/Lenalidomide/Dexamethasone combination or Carfilzomib/Lenalidomide/Dexamethasone or Carfilzomib/Lenalidomide/Bortezomib/Dexamethasone or Ixazomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------If High Risk, The treatments for the patient are Daratumumab/Carfilzomib/Lenalidomide/Dexamethasone or Daratumumab/Cyclophosphamide/Bortezomib/Dexamethasone or Daratumumab/Bortezomib/Thalidomide/Dexamethasone or VTD-PACE. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------If Yes, Does the patient have acute renal insufficiency or have chronic renal insufficiency and/or peripheral neuropathy?
    ----------If Chronic Renal insufficiency and/or Peripheral Neuropathy, The treatments for the patient are Carfilzomib/Cyclophosphamide/Dexamethasone or Ixazomib/Cyclophosphamide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------If Acute Renal Insufficiency, The initial treatment for the patient is Bortezomib/Cyclophosphamide/Dexamethasone. After improvement of the renal function, the treatment for the patient is Bortezomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ------If Yes (frail score >=2), The treatments for the patient are Bortezomib/Dexamethasone or Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    --------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    --------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ----------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ----------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    --------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    --------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ----------------If No, Patient is treated.
    ----------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    --------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    --------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ----------------If No, Patient is treated.
    ----------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----If No, Is the patient frail?
    ------If Yes (frail score >=2), The treatments for the patient are Bortezomib/Dexamethasone or Lenalidomide/Dexamethasone.With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    --------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    --------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ----------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ----------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    --------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    --------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ----------------If No, Patient is treated.
    ----------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    --------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    --------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ----------------If No, Patient is treated.
    ----------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ------If No (frail score <2), Does the patient have either renal insufficiency or peripheral neuropathy?
    --------If No, The treatments for the patient are Bortezomib/Lenalidomide/Dexamethasone or Daratumumab/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------If No, Patient is treated.
    ------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------If No, Patient is treated.
    ------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------If Yes, Does the patient have acute renal insufficiency or have chronic renal insufficiency and/or peripheral neuropathy?
    ----------If Chronic Renal insufficiency and/or Peripheral Neuropathy, The treatments for the patient are Carfilzomib/Cyclophosphamide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------If Acute Renal Insufficiency, The initial treatment for the patient is Bortezomib/Cyclophosphamide/Dexamethasone. After improvement of the renal function, the treatment for the patient is Bortezomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --If Smoldering myeloma (asymptomatic), Is it high risk or low risk?
    ----If Low Risk, Perform primary treatment through a clinical trial OR observe at 3- to 6-month intervals (category 1). For follow-up/surveillance, every 3-6 months keep track of: CBC, differential, platelet count. Creatinine, corrected calcium. Serum quantitative, immunoglobulins, SPEP, SIFE. 24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels. Serum FLC assay. Bone marrow aspirate and biopsy with FISH, SNP array, NGS, or multi-parameter flow cytometry as needed. Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as needed, ideally with the same technique used at diagnosis. After, identify if there is progression to symptomatic myeloma. Is there progression to symptomatic myeloma?
    ------If No, patient is treated.
    ------If Yes, Clinical findings presented are multiple myeloma. Perform myeloma therapy, beginning with Is the patient a transplant candidate?
    --------If Yes, Is the patient frail?
    ----------If No (frail score <2), Does the patient have either renal insufficiency or peripheral neuropathy?
    ------------If No, Is the patient standard or high risk?
    --------------If Standard risk, The treatments for the patient are Bortezomib/Lenalidomide/Dexamethasone combination or Carfilzomib/Lenalidomide/Dexamethasone or Carfilzomib/Lenalidomide/Bortezomib/Dexamethasone or Ixazomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------------If High Risk, The treatments for the patient are Daratumumab/Carfilzomib/Lenalidomide/Dexamethasone or Daratumumab/Cyclophosphamide/Bortezomib/Dexamethasone or Daratumumab/Bortezomib/Thalidomide/Dexamethasone or VTD-PACE. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ------------If Yes, Does the patient have acute renal insufficiency or have chronic renal insufficiency and/or peripheral neuropathy?
    --------------If Chronic Renal insufficiency and/or Peripheral Neuropathy, The treatments for the patient are Carfilzomib/Cyclophosphamide/Dexamethasone or Ixazomib/Cyclophosphamide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------------If Acute Renal Insufficiency, The initial treatment for the patient is Bortezomib/Cyclophosphamide/Dexamethasone. After improvement of the renal function, the treatment for the patient is Bortezomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------If Yes (frail score >=2), The treatments for the patient are Bortezomib/Dexamethasone or Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------If No, Is the patient frail?
    ----------If Yes (frail score >=2), The treatments for the patient are Bortezomib/Dexamethasone or Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------If No (frail score <2), Does the patient have either renal insufficiency or peripheral neuropathy?
    ------------If No, The treatments for the patient are Bortezomib/Lenalidomide/Dexamethasone or Daratumumab/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    --------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    --------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    --------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    --------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ------------If Yes, Does the patient have acute renal insufficiency or have chronic renal insufficiency and/or peripheral neuropathy?
    --------------If Chronic Renal insufficiency and/or Peripheral Neuropathy, The treatments for the patient are Carfilzomib/Cyclophosphamide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------------If Acute Renal Insufficiency, The initial treatment for the patient is Bortezomib/Cyclophosphamide/Dexamethasone. After improvement of the renal function, the treatment for the patient is Bortezomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----If High Risk, Perform primary treatment through a clinical trial (preferred) OR observe at 3-month intervals as clinically indicated OR use Lenalidomide in select patients (category 2B). For follow-up/surveillance, every 3-6 months keep track of: CBC, differential, platelet count. Creatinine, corrected calcium. Serum quantitative, immunoglobulins, SPEP, SIFE. 24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels. Serum FLC assay. Bone marrow aspirate and biopsy with FISH, SNP array, NGS, or multi-parameter flow cytometry as needed. Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as needed, ideally with the same technique used at diagnosis. After, identify if there is progression to symptomatic myeloma. Is there progression to symptomatic myeloma?
    ------If No, patient is treated.
    ------If Yes, Clinical findings presented are multiple myeloma. Perform myeloma therapy, beginning with Is the patient a transplant candidate?
    --------If Yes, Is the patient frail?
    ----------If No (frail score <2), Does the patient have either renal insufficiency or peripheral neuropathy?
    ------------If No, Is the patient standard or high risk?
    --------------If Standard risk, The treatments for the patient are Bortezomib/Lenalidomide/Dexamethasone combination or Carfilzomib/Lenalidomide/Dexamethasone or Carfilzomib/Lenalidomide/Bortezomib/Dexamethasone or Ixazomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------------If High Risk, The treatments for the patient are Daratumumab/Carfilzomib/Lenalidomide/Dexamethasone or Daratumumab/Cyclophosphamide/Bortezomib/Dexamethasone or Daratumumab/Bortezomib/Thalidomide/Dexamethasone or VTD-PACE. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ------------If Yes, Does the patient have acute renal insufficiency or have chronic renal insufficiency and/or peripheral neuropathy?
    --------------If Chronic Renal insufficiency and/or Peripheral Neuropathy, The treatments for the patient are Carfilzomib/Cyclophosphamide/Dexamethasone or Ixazomib/Cyclophosphamide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------------If Acute Renal Insufficiency, The initial treatment for the patient is Bortezomib/Cyclophosphamide/Dexamethasone. After improvement of the renal function, the treatment for the patient is Bortezomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------If Yes (frail score >=2), The treatments for the patient are Bortezomib/Dexamethasone or Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------If No, Is the patient frail?
    ----------If Yes (frail score >=2), The treatments for the patient are Bortezomib/Dexamethasone or Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------If No (frail score <2), Does the patient have either renal insufficiency or peripheral neuropathy?
    ------------If No, The treatments for the patient are Bortezomib/Lenalidomide/Dexamethasone or Daratumumab/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    --------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    --------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    --------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    --------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ------------If Yes, Does the patient have acute renal insufficiency or have chronic renal insufficiency and/or peripheral neuropathy?
    --------------If Chronic Renal insufficiency and/or Peripheral Neuropathy, The treatments for the patient are Carfilzomib/Cyclophosphamide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------------If Acute Renal Insufficiency, The initial treatment for the patient is Bortezomib/Cyclophosphamide/Dexamethasone. After improvement of the renal function, the treatment for the patient is Bortezomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --If Solitary plasmacytoma, Perform primary treatment, either radiation therapy with the possibility of surgery or consider a clinical trial. Afterwards, have a follow-up interval for every 3–6 months to keep track of: CBC, differential, platelet count. Serum chemistry for creatinine, albumin, and corrected calcium. Also keep track of tests as needed: Serum quantitative immunoglobulins, SPEP, with SIFE. 24-h urine for total protein and UPEP with UIFE. Serum FLC assay. Serum LDH and beta-2 microglobulin. Bone marrow aspirate and biopsy. All plasmacytomas should be imaged yearly, preferably with the same technique used at diagnosis, for at least 5 years. After, identify if primary progressive or if there is a response followed by progression. Is there a response followed by progression or is there primary progressive?
    ----If No, patient is treated.
    ----If Yes, Restage with myeloma workup and obtain clinical findings presented as multiple myeloma. Perform myeloma therapy, beginning with Is the patient a transplant candidate?
    ------If Yes, Is the patient frail?
    --------If No (frail score <2), Does the patient have either renal insufficiency or peripheral neuropathy?
    ----------If No, Is the patient standard or high risk?
    ------------If Standard risk, The treatments for the patient are Bortezomib/Lenalidomide/Dexamethasone combination or Carfilzomib/Lenalidomide/Dexamethasone or Carfilzomib/Lenalidomide/Bortezomib/Dexamethasone or Ixazomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    --------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    --------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    --------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    --------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ------------If High Risk, The treatments for the patient are Daratumumab/Carfilzomib/Lenalidomide/Dexamethasone or Daratumumab/Cyclophosphamide/Bortezomib/Dexamethasone or Daratumumab/Bortezomib/Thalidomide/Dexamethasone or VTD-PACE. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    --------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    --------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    --------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    --------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------If Yes, Does the patient have acute renal insufficiency or have chronic renal insufficiency and/or peripheral neuropathy?
    ------------If Chronic Renal insufficiency and/or Peripheral Neuropathy, The treatments for the patient are Carfilzomib/Cyclophosphamide/Dexamethasone or Ixazomib/Cyclophosphamide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    --------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    --------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    --------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    --------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ------------If Acute Renal Insufficiency, The initial treatment for the patient is Bortezomib/Cyclophosphamide/Dexamethasone. After improvement of the renal function, the treatment for the patient is Bortezomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    --------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    --------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    --------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    --------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------If Yes (frail score >=2), The treatments for the patient are Bortezomib/Dexamethasone or Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------If No, Patient is treated.
    ------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------If No, Patient is treated.
    ------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ------If No, Is the patient frail?
    --------If Yes (frail score >=2), The treatments for the patient are Bortezomib/Dexamethasone or Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------If No, Patient is treated.
    ------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------If No, Patient is treated.
    ------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------If No (frail score <2), Does the patient have either renal insufficiency or peripheral neuropathy?
    ----------If No, The treatments for the patient are Bortezomib/Lenalidomide/Dexamethasone or Daratumumab/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------If No, Patient is treated.
    --------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------If Yes, Does the patient have acute renal insufficiency or have chronic renal insufficiency and/or peripheral neuropathy?
    ------------If Chronic Renal insufficiency and/or Peripheral Neuropathy, The treatments for the patient are Carfilzomib/Cyclophosphamide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    --------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    --------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    --------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    --------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ------------If Acute Renal Insufficiency, The initial treatment for the patient is Bortezomib/Cyclophosphamide/Dexamethasone. After improvement of the renal function, the treatment for the patient is Bortezomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    --------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    --------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    --------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    --------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --If Monoclonal gammopathies of clinical significance, Is it Monoclonal Gammopathy of Renal Significance (MGRS) or Monoclonal Gammopathy of Neurological Significance (MGNS)?
    ----If MGRS, Evaluate for kidney disease by analyzing kidney function: eGFR, urinalysis and metabolic testing. Is AKI stage 3, eGFR <60 mL/min and >2ml/min per year decline, Proteinuria (>1 g/day), Albumin:creatinine >30mg/mmol, and Fanconi syndrome OR is AKI stage 1 or 2, eGFR <60 mL/min and <2 mL/min per year decline, Albumin:creatinine 3–30mg/mmol and GFR <60mL/min, Evidence of light chain proteinuria OR is eGFR stable, urinalysis normal and no evidence of light chain proteinuria?
    ------If eGFR stable, urinalysis normal and no evidence of light chain proteinuria, Defer renal biopsy.
    ------If AKI stage 3, eGFR <60 mL/min and >2ml/min per year decline, Proteinuria (>1 g/day), Albumin:creatinine >30mg/mmol, and Fanconi syndrome, Renal biopsy is recommended. After confirm diagnosis of MGRS by: Light microscopy. Immunofluorescence staining for IgG subclasses, IgA and IgM, and kappa and lambda Note: M protein detected in serum and/or urine must match the one found in the renal biopsy. Electron microscopy. PET/CT, low-dose CT, or whole-body MRI as clinically indicated. Bone marrow biopsy if suspected to have MM or WM. Do additional workup as clinically indicated. After, for treatment is MGRS lgG, lgA, or FLC MGRS?
    --------If Yes, perform myeloma therapy, Is the patient a transplant candidate?
    ----------If Yes, Is the patient frail?
    ------------If No (frail score <2), Does the patient have either renal insufficiency or peripheral neuropathy?
    --------------If No, Is the patient standard or high risk?
    ----------------If Standard risk, The treatments for the patient are Bortezomib/Lenalidomide/Dexamethasone combination or Carfilzomib/Lenalidomide/Dexamethasone or Carfilzomib/Lenalidomide/Bortezomib/Dexamethasone or Ixazomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------------If High Risk, The treatments for the patient are Daratumumab/Carfilzomib/Lenalidomide/Dexamethasone or Daratumumab/Cyclophosphamide/Bortezomib/Dexamethasone or Daratumumab/Bortezomib/Thalidomide/Dexamethasone or VTD-PACE. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------------If Yes, Does the patient have acute renal insufficiency or have chronic renal insufficiency and/or peripheral neuropathy?
    ----------------If Chronic Renal insufficiency and/or Peripheral Neuropathy, The treatments for the patient are Carfilzomib/Cyclophosphamide/Dexamethasone or Ixazomib/Cyclophosphamide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------------If Acute Renal Insufficiency, The initial treatment for the patient is Bortezomib/Cyclophosphamide/Dexamethasone. After improvement of the renal function, the treatment for the patient is Bortezomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ------------If Yes (frail score >=2), The treatments for the patient are Bortezomib/Dexamethasone or Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    --------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    --------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    --------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    --------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------If No, Is the patient frail?
    ------------If Yes (frail score >=2), The treatments for the patient are Bortezomib/Dexamethasone or Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    --------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    --------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    --------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    --------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ------------If No (frail score <2), Does the patient have either renal insufficiency or peripheral neuropathy?
    --------------If No, The treatments for the patient are Bortezomib/Lenalidomide/Dexamethasone or Daratumumab/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------------If Yes, Does the patient have acute renal insufficiency or have chronic renal insufficiency and/or peripheral neuropathy?
    ----------------If Chronic Renal insufficiency and/or Peripheral Neuropathy, The treatments for the patient are Carfilzomib/Cyclophosphamide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------------If Acute Renal Insufficiency, The initial treatment for the patient is Bortezomib/Cyclophosphamide/Dexamethasone. After improvement of the renal function, the treatment for the patient is Bortezomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------If No, Is MGRS lgM MGRS or MGRS with monoclonal B-cell lymphocytosis (MBL) features?
    ----------If lgM MGRS, follow NCCN Guidlines for Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphomaa. After, use response criteria for WM. Then measure relapse and individualize treatment based on response and toxicity of prior therapy, patient’s performance status, and renal function at the time of relapse.
    ----------If MGRS with monoclonal B-cell lymphocytosis (MBL) features, follow NCCN Guidelines for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Then, evaluate renal function and bone marrow involvement or radiologic findings. After, measure relapse and individualize treatment based on response and toxicity of prior therapy, patient’s performance status, and renal function at the time of relapse.
    ------If AKI stage 1 or 2, eGFR <60 mL/min and <2 mL/min per year decline, Albumin:creatinine 3–30mg/mmol and GFR <60mL/min, Evidence of light chain proteinuria, Consider renal biopsy.After confirm diagnosis of MGRS by: Light microscopy. Immunofluorescence staining for IgG subclasses, IgA and IgM, and kappa and lambda Note: M protein detected in serum and/or urine must match the one found in the renal biopsy. Electron microscopy. PET/CT, low-dose CT, or whole-body MRI as clinically indicated. Bone marrow biopsy if suspected to have MM or WM. Do additional workup as clinically indicated. After, for treatment is MGRS lgG, lgA, or FLC MGRS?
    --------If Yes, perform myeloma therapy, Is the patient a transplant candidate?
    ----------If Yes, Is the patient frail?
    ------------If No (frail score <2), Does the patient have either renal insufficiency or peripheral neuropathy?
    --------------If No, Is the patient standard or high risk?
    ----------------If Standard risk, The treatments for the patient are Bortezomib/Lenalidomide/Dexamethasone combination or Carfilzomib/Lenalidomide/Dexamethasone or Carfilzomib/Lenalidomide/Bortezomib/Dexamethasone or Ixazomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------------If High Risk, The treatments for the patient are Daratumumab/Carfilzomib/Lenalidomide/Dexamethasone or Daratumumab/Cyclophosphamide/Bortezomib/Dexamethasone or Daratumumab/Bortezomib/Thalidomide/Dexamethasone or VTD-PACE. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------------If Yes, Does the patient have acute renal insufficiency or have chronic renal insufficiency and/or peripheral neuropathy?
    ----------------If Chronic Renal insufficiency and/or Peripheral Neuropathy, The treatments for the patient are Carfilzomib/Cyclophosphamide/Dexamethasone or Ixazomib/Cyclophosphamide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------------If Acute Renal Insufficiency, The initial treatment for the patient is Bortezomib/Cyclophosphamide/Dexamethasone. After improvement of the renal function, the treatment for the patient is Bortezomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ------------If Yes (frail score >=2), The treatments for the patient are Bortezomib/Dexamethasone or Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    --------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    --------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    --------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    --------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------If No, Is the patient frail?
    ------------If Yes (frail score >=2), The treatments for the patient are Bortezomib/Dexamethasone or Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    --------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    --------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    --------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    --------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    --------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ----------------------If No, Patient is treated.
    ----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ------------If No (frail score <2), Does the patient have either renal insufficiency or peripheral neuropathy?
    --------------If No, The treatments for the patient are Bortezomib/Lenalidomide/Dexamethasone or Daratumumab/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ----------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ----------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    ------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    ------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    --------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ----------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    --------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ----------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ----------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    ------------------------If No, Patient is treated.
    ------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------------If Yes, Does the patient have acute renal insufficiency or have chronic renal insufficiency and/or peripheral neuropathy?
    ----------------If Chronic Renal insufficiency and/or Peripheral Neuropathy, The treatments for the patient are Carfilzomib/Cyclophosphamide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    ----------------If Acute Renal Insufficiency, The initial treatment for the patient is Bortezomib/Cyclophosphamide/Dexamethasone. After improvement of the renal function, the treatment for the patient is Bortezomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
    ------------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
    ------------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
    --------------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
    --------------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
    ----------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
    ------------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
    ----------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
    ------------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
    ------------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
    --------------------------If No, Patient is treated.
    --------------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
    --------If No, Is MGRS lgM MGRS or MGRS with monoclonal B-cell lymphocytosis (MBL) features?
    ----------If lgM MGRS, follow NCCN Guidlines for Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphomaa. After, use response criteria for WM. Then measure relapse and individualize treatment based on response and toxicity of prior therapy, patient’s performance status, and renal function at the time of relapse.
    ----------If MGRS with monoclonal B-cell lymphocytosis (MBL) features, follow NCCN Guidelines for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Then, evaluate renal function and bone marrow involvement or radiologic findings. After, measure relapse and individualize treatment based on response and toxicity of prior therapy, patient’s performance status, and renal function at the time of relapse.
    ----If MGNS, rule out other causes of neuropathy: Diabetes, Cobalamin deficiency, Thyroid dysfunction, Lyme disease, HIV infection, Syphilis, Autoimmune disease, Cryoglobulinemia, Evaluation for light chain amyloidosis, Anti-MAG antibodiesa, Ganglioside antibody panel, Nerve conduction study (NCS)/electromyogram (EMG), Neurology consult, MYD88 L265P allele-specific PCR (AS-PCR) testing of bone marrow, Chest/abdominal/pelvic CT with contrast when possible. After are clinical flindings high suspicion or low suspicion?
    ------If High Suspicion, findings must have or be Sensory predominant, Length dependent, Slow progression (years), Bilateral and symmetrical, Antibodies present, Demyelination by EMG/NCS OR intermediate suspicion (not high or low suspicion) AND affecting activities of daily living (ADLs). After observation should be done and NCCN Guidlines for Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphomaa should be followed.
    ------If Low Suspicion, findings must have or be Motor/pain predominant, Non-length dependent, Rapid progression (weeks to months), Unilateral/asymmetrical, Antibodies not present, No Demyelination by EMG/NCS OR intermediate/high suspicion AND not affecting ADLs. After observation should be done and NCCN Guidlines for Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphomaa should be followed.`,
    `are you happy?
    --if yes, then great
    --if meh, then get a lollipop. did that help?
    ----if a lot, then great
    ----if a little, then get another one
    --if no, then see a shrink
    --if not interested, which of these topics are you interested in: myeloma diagnosis, social security card, student visa?
    ----if interested in NYU, DOCUMENT: https://www.nyu.edu
    ----if interested in myeloma, DECISIONTREE: https://elliot2878.github.io/decision_tree.github.io/myeloma.txt
    ----if interested in APPLE, DOCUMENT: https://www.apple.com`,
    `CART:
    |--- petal width (cm) <= 0.80
    |   |--- class: 0
    |--- petal width (cm) > 0.80
    |   |--- petal width (cm) <= 1.75
    |   |   |--- class: 1
    |   |--- petal width (cm) >  1.75
    |   |   |--- class: 2`,
    `what is broken?
    --if doesn't turn on, check the battery
    --if its screen flashes, take to the store. Do they have to send it out?
    ----if yes, ask for a loaner.
    ----if no, go to the movies.`,
    `Are you here to apply for a visa? If so, Is your country on this list (https://visaguide.world/us-visa/nonimmigrant/visitor/visa-waiver-program/)
    --If Yes, you do not need a visa to enter the United States!
    --If No, what type of visa are you applying for?
    ----If F1/F2 student visa, do you have a passport?
    ------If Yes, have you ever been arrested or convicted for an offense or crime?
    --------If Yes, please consult the https://ceac.state.gov/genniv/ to see if you qualify for a visa.
    --------If No, have you ever engaged in a conspiracy to violate any law relating to controlled substances?
    ----------If Yes, please consult the https://ceac.state.gov/genniv/ to see if you qualify for a visa.
    ----------If No, have you ever been involved in money laundering?
    ------------If Yes, please consult the https://ceac.state.gov/genniv/ to see if you qualify for a visa.
    ------------If No, you qualify for a student visa! The next steps of this process include sending a photograph, follow this site for guidelines: https://visaguide.world/us-visa/photo-requirements/. Lastly, you need to schedule an interview. Please visit this website for more information: https://visaguide.world/us-visa/fees/. 
    ------If No, you do not qualify for a visa.
    ----If B1/B2 visitor visa, is your intent for visiting the United States business-related?
    ------If Yes, do you intend to return to your home country as soon as your visa expires?
    --------If Yes, do you have a passport?
    ----------If Yes, have you ever been arrested or convicted for an offense or crime?
    ------------If Yes, please consult the https://ceac.state.gov/genniv/ to see if you qualify for a visa.
    ------------If No, have you ever engaged in a conspiracy to violate any law relating to controlled substances?
    --------------If Yes, please consult the https://ceac.state.gov/genniv/ to see if you qualify for a visa.
    --------------If No, you qualify for a business visa! Please consult https://visaguide.world/us-visa/nonimmigrant/visitor/b1/ to see the next steps in this process.
    ----------If No, you do not qualify for a visa.
    ------If No, you are applying for the wrong visa!
    ----If M1 visa, have you been accepted by a Student Exchange Visitor Program?
    ------If Yes, will you be able to finance your education and stay once you are in the United States?
    --------If Yes, you qualify for an M1 visa! Please visit https://visaguide.world/us-visa/nonimmigrant/study-exchange-visas/m1/ for more details.
    --------If No, sorry, you do not qualify for this type of visa. Please visit  https://ceac.state.gov/genniv/ to see if you qualify for a visa.
    ------If No, sorry, you do not qualify for this type of visa. Please visit  https://ceac.state.gov/genniv/ to see if you qualify for a visa.
    
    
    ----If J1 visa, which role are you applying as?
    ------If Au Pair, Are you between the age of 18-26 years old, proficient in English, and a secondary school graduate?
    --------If Yes, you qualify for a J1 visa! Please consult https://visaguide.world/us-visa/nonimmigrant/study-exchange-visas/j1/ to see the next steps in this process.
    --------If No, you do not qualify for this specific type of J1 visa. Perhaps you could see if you are eligible for other types of visas at https://visaguide.world/us-visa/ 
    ------If Camp Counselor, are you at least 18 years old and proficient in English?
    --------If Yes, you qualify for a J1 visa! Please consult https://visaguide.world/us-visa/nonimmigrant/study-exchange-visas/j1/ to see the next steps in this process.
    --------If No, you do not qualify for this specific type of J1 visa. Perhaps you could see if you are eligible for other types of visas at https://visaguide.world/us-visa/ 
    ------If Professor/Research Scholar, are you a candidate for a tenure track?
    --------If Yes, you do not qualify for this specific type of J1 visa. Perhaps you could see if you are eligible for other types of visas at https://visaguide.world/us-visa/ 
    --------If No, have you participated in a J1 visa program in the last 12 months?
    ----------If Yes, you do not qualify for this specific type of J1 visa. Perhaps you could see if you are eligible for other types of visas at https://visaguide.world/us-visa/ 
    ----------If No, have you been a part of a professorship program in the past 24 months?
    ------------If Yes, you do not qualify for this specific type of J1 visa. Perhaps you could see if you are eligible for other types of visas at https://visaguide.world/us-visa/ 
    ------------If No, you are eligible for a J1 visa! Please visit https://visaguide.world/us-visa/nonimmigrant/study-exchange-visas/j1/ to see your next steps in the process.
    ------If not listed, please visit https://visaguide.world/us-visa/nonimmigrant/study-exchange-visas/j1/ to find the next steps in finding a J1 visa type that is specific to your needs.
    ----If Q visa, are you at least 18 years old?
    ------If Yes, are you knowledgeable or skillful enough to communicate the cultural aspects of your home country?
    --------If Yes, you must demonstrate that you're eligible to return to your home country once your Q visa expires. please continue with your application on this page https://https://visaguide.world/us-visa/nonimmigrant/study-exchange-visas/q1/
    --------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ----If H1B visa, will your employer petition for you to receive an H1B visa?
    ------If Yes, you must notify your employer that the deadline for petitions is March 2. Please continue with the next steps in your application at this page https://https://visaguide.world/us-visa/nonimmigrant/employment/h1b/
    ------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ----If O-type visa, which O visa are you applying for?
    ------If O1 visa, would you consider yourself to have extraordinary expertise in your speciality?
    --------If Yes, you must follow the steps on this page, https://visaguide.world/us-visa/nonimmigrant/employment/o1/. Your employer will have to file a petition with the USCIS on your behalf.
    --------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ------If O2 visa, are you an assistant to someone of extraordinary expertise in their respective field?
    --------If Yes, you must be a "critical" member of the performance or work of the O1 visa holder. If you consider yourself such a candidate continue with the steps on this page https://visaguide.world/us-visa/nonimmigrant/employment/o1/o2/ 
    --------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ------If O3 visa, are you an immediate family member of an O1 visa or O2 visa holder?
    --------If yes, you qualify for an O3 visa and should continue with your application on this page https://visaguide.world/us-visa/nonimmigrant/employment/o1/o3/.
    --------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas. 
    ----If P-type visa, are you a part of an internationally recognized sports organization or entertainment group?
    ------If Yes, please visit https://visaguide.world/us-visa/nonimmigrant/employment/p1/ for the next steps in your application 
    ------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas. 
    ----If I visa, which I-type visa are you applying for?
    ------If IR1 visa, are you the spouse or child of a US citizen?
    --------If Yes, please visit  https://visaguide.world/us-visa/green-card/marriage/ for the next steps in your visa application.
    --------If No, 
    ------If IR2 visa, are you under 21 years old?
    --------If Yes, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    --------If No, are you unmarried?
    ----------If Yes, are you currently living in a foreign country, or have you been living with adoptive US citizen parents for at least 2 years?
    ------------If Yes, please visit https://visaguide.world/us-visa/immigrant/ir2/ to continue with the next steps of your application.
    ----------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ------If IR3 visa, do you plan to adopt a child from a foreign country?
    --------If Yes, is the child from a "Hague" adoption country (list of hague adoption countries, https://visaguide.world/us-visa/immigrant/ir3/.?)?
    ----------If Yes, is the child under 21 years old?
    ------------If Yes, do you have a valid US address?
    --------------If Yes, please visit https://visaguide.world/us-visa/immigrant/ir3/ to follow the process of applying for an IR3 visa for a child from a Hague country.
    --------------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ------------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ----------If No, please visit https://visaguide.world/us-visa/immigrant/ir3/ to read about the process of adopting a child from a non-hague adoption country.
    --------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ------If IR4 visa, is the child from a "Hague" adoption country (list of hague adoption countries, https://visaguide.world/us-visa/immigrant/ir3/.?)?
    --------If Yes, is the child under 21 years old?
    ----------If Yes, do you have a valid US address?
    ------------If Yes, please visit https://visaguide.world/us-visa/immigrant/ir4/ to read about adopting a child from a Hague country.
    ------------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ----------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    --------If No, If No, please visit https://visaguide.world/us-visa/immigrant/ir3/ to read about the process of adopting a child from a non-hague adoption country.
    ----If E-type visa, which type of E-type visa are you applying for?
    ------If E1 type visa, are you involved with international trade?
    --------If Yes, does your home country have a trade treaty with the US?
    ----------If Yes, do you hold a senior position such as director, manager, supervisor, or executive?
    ------------If Yes, you qualify for an E1 visa! Please visit https://visaguide.world/us-visa/nonimmigrant/e1/ to see the next steps in the process of applying for a visa.
    ------------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ----------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    --------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ------If E2 type visa, are you an individual investor or a company?
    --------If individual, are you from a country that has an investment treaty with the US?
    ----------If Yes, do you have the intent to invest a substantial amount of capital into a bona fide business?
    ------------If Yes, do you have the goal of developing the business further through that investment?
    --------------If Yes, do you understand and agree to put the funds for the investment in an account until the visa is approved?
    ----------------If Yes, you qualify for an E2 visa!, please visit https://visaguide.world/us-visa/nonimmigrant/e2/ to see the next steps in the process.
    ----------------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    --------------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ------------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ----------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    --------If company, is your company owned by at least 50% of people from a treaty investment country?
    ----------If Yes, do you have the intent to invest a substantial amount of capital into a bona fide business?
    ------------If Yes, do you have the goal of developing the business further through that investment?
    --------------If Yes, do you understand and agree to put the funds for the investment in an account until the visa is approved?
    ----------------If Yes, you qualify for an E2 visa!, please visit https://visaguide.world/us-visa/nonimmigrant/e2/ to see the next steps in the process.
    ----------------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    --------------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ------------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ----------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ----If U visa, are you a victim of one of the crimes listed here, https://visaguide.world/us-visa/nonimmigrant/u-visa/ ?
    ------If Yes, have you suffered physical or mental illness as a result of this crime?
    --------If Yes, are you willing to cooperate with the US government regarding this crime?
    ----------If Yes, do you have information about the crime that you are able to share with the US government?
    ------------If Yes, you may qualify for a U visa! please visit https://visaguide.world/us-visa/nonimmigrant/u-visa/ to see the next steps in the application process.
    ------------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ----------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    --------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ----If F22-type visa, which F22-type visa are you applying for?
    ------If F22A, are you under the age of 21 years old?
    --------If Yes, are you unmarried?
    ----------If Yes, are you able to prove your relationship with your visa sponsor in the United States?
    ------------If Yes, you may qualify for an F2A visa! Please visit https://visaguide.world/us-visa/immigrant/f2a/ to see the next steps in the application process.
    ------------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ----------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    --------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ------If F22B, are you the child of a US Lawful Permanent Resident?
    --------If Yes, are you over the age of 21 years old?
    ----------If Yes, are you unmarried?
    ------------If Yes, you may qualify for an F2B visa! Please visit https://visaguide.world/us-visa/immigrant/f2b/ to see the next steps in the application process for an F2B visa.
    ------------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ----------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    --------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ----If K3 visa, are you legally married to a US citizen?
    ------If Yes, has your significant other filed an I-130 form in your name?
    --------If Yes, you may qualify for a K3 visa! Please visit https://visaguide.world/us-visa/immigrant/k3/ to see the next steps in your application process.
    --------If No, has your significant other filed an I-130 form in your name if so you continue in the application process for a K3 visa.
    ------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ----If EB1 visa, 1) You have extraordinary abilities in arts, sciences, education, athletics, and business, 2) You have outstanding professors and researchers who have received international recognition for your contribution in your field, 3) You are a multinational manager or executive who has been working for an international branch of a US company for at least 1 year. Do you have one of the previous characteristics?
    ------If 1, please visit https://visaguide.world/us-visa/immigrant/eb1/ to see if you have any of the qualifying accolades on this list. Do you have any of the previous accolades?
    --------If Yes, you may qualify for an EB1 visa. Please visit https://visaguide.world/us-visa/immigrant/eb1/ to see the next steps in the application process.
    --------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ------If 2, please visit https://visaguide.world/us-visa/immigrant/eb1/ to see if you have any of the qualifying accolades on this list. Do you have any of the previous accolades?
    --------If Yes, you may qualify for an EB1 visa. Please visit https://visaguide.world/us-visa/immigrant/eb1/ to see the next steps in the application process. 
    --------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ------If 3, please visit https://visaguide.world/us-visa/immigrant/eb1/ to see if you have any of the qualifying accolades on this list. Do you have any of the previous accolades?
    --------If Yes, you may qualify for an EB1 visa. Please visit https://visaguide.world/us-visa/immigrant/eb1/ to see the next steps in the application process.
    --------If No, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ------If None, please visit https://visaguide.world/us-visa/ to see if you qualify for other visas.
    ----If visa not listed, please consult this website https://visaguide.world/us-visa/ to see if you qualify for a visa.`,
    `how many bedrooms you need?
    --if one, how many square feet?
    ----if between 1500 to 3000, do you want a swimming pool?
    ------if yes, SQL: select * from houses where num_of_bedrooms = 1  and square_feet > 1500 and square_feet < 3000 and swimming_pool = 'Y'; 
    ------if no, SQL: select * from houses where num_of_bedrooms = 1  and square_feet > 1500 and square_feet < 3000 and swimming_pool = 'N'; 
    ----if more than 3000, do you want a swimming pool?
    ------if yes, SQL: select * from houses where num_of_bedrooms = 1  and square_feet > 3000 and swimming_pool = 'Y'; 
    ------if no, SQL: select * from houses where num_of_bedrooms = 1  and square_feet > 3000 and swimming_pool = 'N'; 
    --if two, how many square feet?
    ----if between 1500 to 3000, do you want a swimming pool?
    ------if yes, SQL: select * from houses where num_of_bedrooms = 2  and square_feet < 1500 and square_feet > 3000 and swimming_pool = 'Y'; 
    ------if no, SQL: select * from houses where num_of_bedrooms = 2  and square_feet < 1500 and square_feet > 3000 and swimming_pool = 'N'; 
    ----if more than 3000, do you want a swimming pool?
    ------if yes, SQL: select * from houses where num_of_bedrooms = 2  and square_feet > 3000 and swimming_pool = 'Y'; 
    ------if no, SQL: select * from houses where num_of_bedrooms = 2  and square_feet > 3000 and swimming_pool = 'N'; 
    --if three, how many square feet?
    ----if between 1500 to 3000, do you want a swimming pool?
    ------if yes, SQL: select * from houses where num_of_bedrooms = 3  and square_feet < 1500 and square_feet > 3000 and swimming_pool = 'Y'; 
    ------if no, SQL: select * from houses where num_of_bedrooms = 3  and square_feet < 1500 and square_feet > 3000 and swimming_pool = 'N'; 
    ----if more than 3000, do you want a swimming pool?
    ------if yes, SQL: select * from houses where num_of_bedrooms = 3  and square_feet > 3000 and swimming_pool = 'Y'; 
    ------if no, SQL: select * from houses where num_of_bedrooms = 3  and square_feet > 3000 and swimming_pool = 'N'; `,
    `Are you above the age of 62?
    --If yes, do you have your original birth certificate?
    ----If no, you are not eligible to file for social security.
    ----If yes, do you have proof of U.S. Citizenship or lawful alien status if you were not born in the United States?
    ------If no, you are not eligible to file for social security.
    ------If yes, have you served in the United States military?
    --------If yes, do you have your service papers?
    ----------If no, you are not eligible to file for social security.
    ----------If yes, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ------------If no, you are not eligible to file for social security.
    ------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    --------------If no, you are not eligible to file for social security.
    --------------If yes, you qualify for social security benefits!
    --------If no, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ----------If no, you are not eligible to file for social security.
    ----------If yes, do you have the name and address of your employer over the last two years and proof of income?
    ------------If yes, you qualify for social security benefits!
    ------------If no, you are not eligible to file for social security.
    --------If no, you are not eligible to file for social security.
    --If no, are you disabled?
    ----If yes, how old are you?
    ------If younger than 24, do you have at least 6 work credits (You earn one work credit for making $1,510 in wages or self-employment income in a year. The maximum amount of work credits you can earn in a year is four.)?
    --------If yes, Do you have your original birth certificate?
    ----------If no, you are not eligible to file for social security.
    ----------If yes, do you have proof of U.S. Citizenship or lawful alien status if you were not born in the United States?
    ------------If no, you are not eligible to file for social security.
    ------------If yes, have you served in the United States military?
    --------------If yes, do you have your service papers?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ------------------If no, you are not eligible to file for social security.
    ------------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    --------------------If no, you are not eligible to file for social security.
    --------------------If yes, you qualify for social security benefits!
    --------------If no, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    ------------------If yes, you qualify for social security benefits!
    ------------------If no, you are not eligible to file for social security.
    --------If no, you do not qualify for social security benefits!
    ------If 24 - 31 years old, do you have at least 14 work credits (You earn one work credit for making $1,510 in wages or self-employment income in a year. The maximum amount of work credits you can earn in a year is four.)?
    --------If yes, Do you have your original birth certificate?
    ----------If no, you are not eligible to file for social security.
    ----------If yes, do you have proof of U.S. Citizenship or lawful alien status if you were not born in the United States?
    ------------If no, you are not eligible to file for social security.
    ------------If yes, have you served in the United States military?
    --------------If yes, do you have your service papers?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ------------------If no, you are not eligible to file for social security.
    ------------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    --------------------If no, you are not eligible to file for social security.
    --------------------If yes, you qualify for social security benefits!
    --------------If no, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    ------------------If yes, you qualify for social security benefits!
    ------------------If no, you are not eligible to file for social security.
    --------If no, you do not qualify for social security benefits!
    ------If 31 - 42 years old, do you have at least 20 work credits (You earn one work credit for making $1,510 in wages or self-employment income in a year. The maximum amount of work credits you can earn in a year is four.)?
    --------If yes, Do you have your original birth certificate?
    ----------If no, you are not eligible to file for social security.
    ----------If yes, do you have proof of U.S. Citizenship or lawful alien status if you were not born in the United States?
    ------------If no, you are not eligible to file for social security.
    ------------If yes, have you served in the United States military?
    --------------If yes, do you have your service papers?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ------------------If no, you are not eligible to file for social security.
    ------------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    --------------------If no, you are not eligible to file for social security.
    --------------------If yes, you qualify for social security benefits!
    --------------If no, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    ------------------If yes, you qualify for social security benefits!
    ------------------If no, you are not eligible to file for social security.
    --------If no, you do not qualify for social security benefits!
    ------If 42 - 44 years old, do you have at least 22 work credits (You earn one work credit for making $1,510 in wages or self-employment income in a year. The maximum amount of work credits you can earn in a year is four.)?
    --------If yes, Do you have your original birth certificate?
    ----------If no, you are not eligible to file for social security.
    ----------If yes, do you have proof of U.S. Citizenship or lawful alien status if you were not born in the United States?
    ------------If no, you are not eligible to file for social security.
    ------------If yes, have you served in the United States military?
    --------------If yes, do you have your service papers?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ------------------If no, you are not eligible to file for social security.
    ------------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    --------------------If no, you are not eligible to file for social security.
    --------------------If yes, you qualify for social security benefits!
    --------------If no, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    ------------------If yes, you qualify for social security benefits!
    ------------------If no, you are not eligible to file for social security.
    --------If no, you do not qualify for social security benefits!
    ------If 44 - 46 years old, do you have at least 24 work credits (You earn one work credit for making $1,510 in wages or self-employment income in a year. The maximum amount of work credits you can earn in a year is four.)?
    --------If yes, Do you have your original birth certificate?
    ----------If no, you are not eligible to file for social security.
    ----------If yes, do you have proof of U.S. Citizenship or lawful alien status if you were not born in the United States?
    ------------If no, you are not eligible to file for social security.
    ------------If yes, have you served in the United States military?
    --------------If yes, do you have your service papers?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ------------------If no, you are not eligible to file for social security.
    ------------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    --------------------If no, you are not eligible to file for social security.
    --------------------If yes, you qualify for social security benefits!
    --------------If no, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    ------------------If yes, you qualify for social security benefits!
    ------------------If no, you are not eligible to file for social security.
    --------If no, you do not qualify for social security benefits!
    ------If 46 - 48 years old, do you have at least 26  (You earn one work credit for making $1,510 in wages or self-employment income in a year. The maximum amount of work credits you can earn in a year is four.)?
    --------If yes, Do you have your original birth certificate?
    ----------If no, you are not eligible to file for social security.
    ----------If yes, do you have proof of U.S. Citizenship or lawful alien status if you were not born in the United States?
    ------------If no, you are not eligible to file for social security.
    ------------If yes, have you served in the United States military?
    --------------If yes, do you have your service papers?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ------------------If no, you are not eligible to file for social security.
    ------------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    --------------------If no, you are not eligible to file for social security.
    --------------------If yes, you qualify for social security benefits!
    --------------If no, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    ------------------If yes, you qualify for social security benefits!
    ------------------If no, you are not eligible to file for social security.
    --------If no, you do not qualify for social security benefits!
    ------If 48 - 50 years old, do you have at least 28  (You earn one work credit for making $1,510 in wages or self-employment income in a year. The maximum amount of work credits you can earn in a year is four.)?
    --------If yes, Do you have your original birth certificate?
    ----------If no, you are not eligible to file for social security.
    ----------If yes, do you have proof of U.S. Citizenship or lawful alien status if you were not born in the United States?
    ------------If no, you are not eligible to file for social security.
    ------------If yes, have you served in the United States military?
    --------------If yes, do you have your service papers?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ------------------If no, you are not eligible to file for social security.
    ------------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    --------------------If no, you are not eligible to file for social security.
    --------------------If yes, you qualify for social security benefits!
    --------------If no, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    ------------------If yes, you qualify for social security benefits!
    ------------------If no, you are not eligible to file for social security.
    --------If no, you do not qualify for social security benefits!
    ------If 52 - 54 years old, do you have at least 30 (You earn one work credit for making $1,510 in wages or self-employment income in a year. The maximum amount of work credits you can earn in a year is four.)?
    --------If yes, Do you have your original birth certificate?
    ----------If no, you are not eligible to file for social security.
    ----------If yes, do you have proof of U.S. Citizenship or lawful alien status if you were not born in the United States?
    ------------If no, you are not eligible to file for social security.
    ------------If yes, have you served in the United States military?
    --------------If yes, do you have your service papers?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ------------------If no, you are not eligible to file for social security.
    ------------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    --------------------If no, you are not eligible to file for social security.
    --------------------If yes, you qualify for social security benefits!
    --------------If no, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    ------------------If yes, you qualify for social security benefits!
    ------------------If no, you are not eligible to file for social security.
    --------If no, you do not qualify for social security benefits!
    ------If 54 - 56 years old, do you have at least 32  (You earn one work credit for making $1,510 in wages or self-employment income in a year. The maximum amount of work credits you can earn in a year is four.)?
    --------If yes, Do you have your original birth certificate?
    ----------If no, you are not eligible to file for social security.
    ----------If yes, do you have proof of U.S. Citizenship or lawful alien status if you were not born in the United States?
    ------------If no, you are not eligible to file for social security.
    ------------If yes, have you served in the United States military?
    --------------If yes, do you have your service papers?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ------------------If no, you are not eligible to file for social security.
    ------------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    --------------------If no, you are not eligible to file for social security.
    --------------------If yes, you qualify for social security benefits!
    --------------If no, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    ------------------If yes, you qualify for social security benefits!
    ------------------If no, you are not eligible to file for social security.
    --------If no, you do not qualify for social security benefits!
    ------If 56 - 58 years old, do you have at least 34 work credits (You earn one work credit for making $1,510 in wages or self-employment income in a year. The maximum amount of work credits you can earn in a year is four.)?
    --------If yes, Do you have your original birth certificate?
    ----------If no, you are not eligible to file for social security.
    ----------If yes, do you have proof of U.S. Citizenship or lawful alien status if you were not born in the United States?
    ------------If no, you are not eligible to file for social security.
    ------------If yes, have you served in the United States military?
    --------------If yes, do you have your service papers?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ------------------If no, you are not eligible to file for social security.
    ------------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    --------------------If no, you are not eligible to file for social security.
    --------------------If yes, you qualify for social security benefits!
    --------------If no, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    ------------------If yes, you qualify for social security benefits!
    ------------------If no, you are not eligible to file for social security.
    --------If no, you do not qualify for social security benefits!
    ------If 58 - 60 years old, do you have at least 36 work credits (You earn one work credit for making $1,510 in wages or self-employment income in a year. The maximum amount of work credits you can earn in a year is four.)?
    --------If yes, Do you have your original birth certificate?
    ----------If no, you are not eligible to file for social security.
    ----------If yes, do you have proof of U.S. Citizenship or lawful alien status if you were not born in the United States?
    ------------If no, you are not eligible to file for social security.
    ------------If yes, have you served in the United States military?
    --------------If yes, do you have your service papers?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ------------------If no, you are not eligible to file for social security.
    ------------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    --------------------If no, you are not eligible to file for social security.
    --------------------If yes, you qualify for social security benefits!
    --------------If no, do you have a copy of your W-2 forms and/or your self-employment tax returns?
    ----------------If no, you are not eligible to file for social security.
    ----------------If yes, do you have the name and address of your employer over the last two years and proof of income?
    ------------------If yes, you qualify for social security benefits!
    ------------------If no, you are not eligible to file for social security.
    --------If no, you do not qualify for social security benefits!
    ----If no, you are eligible to file for social security benefits, but you will withdraw with penalities. 
    `,
]